Nuvalent (NUVL) Stock Price, News & Analysis

$64.49
+1.73 (+2.76%)
(As of 04/22/2024 ET)
Today's Range
$62.23
$64.96
50-Day Range
$62.76
$88.99
52-Week Range
$33.03
$89.39
Volume
454,885 shs
Average Volume
445,537 shs
Market Capitalization
$4.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.78

Nuvalent MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
40.8% Upside
$90.78 Price Target
Short Interest
Bearish
20.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Nuvalent in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$78.25 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.89) to ($3.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.89 out of 5 stars

Medical Sector

381st out of 910 stocks

Pharmaceutical Preparations Industry

169th out of 426 stocks

NUVL stock logo

About Nuvalent Stock (NASDAQ:NUVL)

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

NUVL Stock Price History

NUVL Stock News Headlines

Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
Nuvalent (NASDAQ:NUVL) Now Covered by Jefferies Financial Group
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
NUVL Apr 2024 100.000 call
Recap: Nuvalent Q4 Earnings
Nuvalent, Inc. Q4 Loss increases, misses estimates
See More Headlines
Receive NUVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/22/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NUVL
Fax
N/A
Employees
92
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$90.78
High Stock Price Target
$110.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+41.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-126,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$10.94 per share

Miscellaneous

Free Float
54,605,000
Market Cap
$4.10 billion
Optionable
Optionable
Beta
1.30
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. James R. Porter Ph.D. (Age 48)
    CEO, President & Director
    Comp: $998.02k
  • Prof. Matthew D. Shair Ph.D. (Age 55)
    Founder, Head of Scientific Advisory Board & Director
    Comp: $235k
  • Ms. Alex Balcom CPA (Age 39)
    M.B.A., CFO & Treasurer
    Comp: $654.22k
  • Dr. Christopher D. Turner M.D. (Age 55)
    Chief Medical Officer
    Comp: $714.26k
  • Dr. Benjamin Lane Ph.D.
    Senior Vice President of Technical Operations
  • Ms. Deborah Ann Miller J.D.Ms. Deborah Ann Miller J.D. (Age 48)
    Ph.D., Chief Legal Officer & Secretary
    Comp: $595.96k
  • Mr. Matthew Metivier
    Senior Vice President of Human Resources
  • Ms. Darlene NociMs. Darlene Noci (Age 46)
    Chief Development Officer
  • Mr. Henry Pelish Ph.D.
    Senior Vice President of Drug Discovery
  • Mr. John Soglia Ph.D.
    Senior Vice President of Translational Development

NUVL Stock Analysis - Frequently Asked Questions

Should I buy or sell Nuvalent stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVL shares.
View NUVL analyst ratings
or view top-rated stocks.

What is Nuvalent's stock price target for 2024?

10 Wall Street research analysts have issued 12 month price targets for Nuvalent's shares. Their NUVL share price targets range from $42.00 to $110.00. On average, they predict the company's share price to reach $90.78 in the next year. This suggests a possible upside of 40.8% from the stock's current price.
View analysts price targets for NUVL
or view top-rated stocks among Wall Street analysts.

How have NUVL shares performed in 2024?

Nuvalent's stock was trading at $73.59 at the beginning of the year. Since then, NUVL stock has decreased by 12.4% and is now trading at $64.49.
View the best growth stocks for 2024 here
.

When is Nuvalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our NUVL earnings forecast
.

How were Nuvalent's earnings last quarter?

Nuvalent, Inc. (NASDAQ:NUVL) released its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.02.

When did Nuvalent IPO?

Nuvalent (NUVL) raised $151 million in an initial public offering on Thursday, July 29th 2021. The company issued 8,900,000 shares at $16.00-$18.00 per share.

Who are Nuvalent's major shareholders?

Nuvalent's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Capital LLC (0.03%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Alexandra Balcom, Andrew A F Hack, Anna Protopapas, Christopher Durant Turner, Darlene Noci, Deborah Ann Miller and Matthew Shair.
View institutional ownership trends
.

How do I buy shares of Nuvalent?

Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NUVL) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners